

## Transgene Announces Presentations at Upcoming Investor Conferences

**Strasbourg, France, October 29, 2013** – Transgene today announced that management will present at several investor conferences in November and December as outlined below.

| <b>Date</b>    | <b>Event</b>   | <b>Location</b>        |
|----------------|--|------------------------|
| November 20-21 | Jefferies Global Healthcare Conference                             | London, United Kingdom |
| November 21    | Rendez-Vous des Entreprises Cotées                                 | Strasbourg, France     |
| November 27    | Séminaire Biotech Portzamparc                                      | Paris, France          |
| December 4     | MC Services Healthcare Forum, Munich<br>Capital Markets Conference | Munich, Germany        |

### **About Transgene**

Transgene, a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of oncology and infectious diseases. Transgene's programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company's four clinical-stage programs are: TG4010 for non-small cell lung cancer; Pexa-Vec for liver cancer; TG4001 for oropharyngeal cancer (under a collaboration agreement with the EORTC) and TG4040 for chronic Hepatitis C. Transgene has concluded corporate strategic agreements for the development of two of its immunotherapy products: an exclusive option agreement with Novartis for the development and commercialization of TG4010 and an in-licensing agreement with US-based Jennerex, Inc. for the development and commercialization of Pexa-Vec in certain territories. The Company also has several programs in research and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at [www.transgene.fr](http://www.transgene.fr).

### **Contacts:**

#### **Transgene**

Elisabetta Castelli, Director IR, +33 (0)1 44 08 55 05

#### **MC Services**

Raimund Gabriel, +49 89 210 228 30

Shaun Brown, +44 207 148 5998